Re: Denner, my guess/speculation is that he came to Ariad for AP26113; not Iclusig ... unless you have a sales/mktg power of J&J, it's too much effort to turn the Iclusig ship around. AP26113 is the crown jewel of Ariad.
With Iclusig, patients have some weird side effects that really negatively impact their quality of life. Maybe starting off at 15mg will help but many drs start off at 15 only to get the patient's system used to the med. They ultimately want to go to 30 mg or higher. The other TKIs have severe side effects as well and Iclusig is no different.
With AP26113, it's superior vs the competition. Not only on its effectiveness but also on its (lower/minimal) side effects. The quality of life improvement is very significant. Wouldn't surprise me if Denner heard about this, saw the huge opportunity and went hard after the company.
